Body Composition and Inflammation as Emerging Sex-Specific Prognostic Factors in Patients with Advanced Cutaneous Melanoma Undergoing Immune Checkpoint-Inhibition Therapy: A Prospective Pilot Study
Our data suggest that BIA-derived markers are associated with the prognosis of melanoma patients undergoing ICI therapy in a sex-specific manner. Selected body composition parameters correlate differently with blood markers of inflammation and protein metabolism in men and women. If validated in larger trials, these assessments might improve individualized supportive care and clinical risk stratification.
Authors
- Jana Knüver (ORCID: https://orcid.org/0000-0003-1066-6431)
- Sebastian Theurich (ORCID: https://orcid.org/0000-0001-5706-8258)
- Max Schlaak (ORCID: https://orcid.org/0000-0002-1663-8098)
- Lukas Gerecht
- O.D. Persa
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Bonn (DE)
- LMU Klinikum (DE)
- Düsseldorf University Hospital (DE)
- Integrated Oncology (United States) (US)
- University Hospital Cologne (DE)
- Heinrich Heine University Düsseldorf (DE)
- Technical University of Munich (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1159/000546797
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05